SICHUAN GOLDSTONE ASIA PHARMACEUTICAL INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.04 CNY | -1.74% |
|
-1.63% | -18.26% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 3,535 | 3,073 | 3,065 | 4,363 | 5,468 | 4,443 |
| Enterprise Value (EV) 1 | 3,167 | 2,666 | 2,591 | 4,075 | 4,974 | 3,970 |
| P/E ratio | 23.8 x | 25.5 x | -4.46 x | 63.9 x | 25.2 x | 35.7 x |
| Yield | 0.91% | 0.92% | - | - | - | - |
| Capitalization / Revenue | 3.64 x | 3.06 x | 3.94 x | 4.14 x | 4.4 x | 3.67 x |
| EV / Revenue | 3.26 x | 2.65 x | 3.33 x | 3.87 x | 4 x | 3.28 x |
| EV / EBITDA | 12.2 x | 10.9 x | 33.2 x | 20.2 x | 13.4 x | 11.6 x |
| EV / FCF | 22.7 x | 21.7 x | 24.7 x | 149 x | 18.9 x | -204 x |
| FCF Yield | 4.4% | 4.6% | 4.05% | 0.67% | 5.3% | -0.49% |
| Price to Book | 1.34 x | 1.12 x | 1.52 x | 2.09 x | 2.4 x | 2.02 x |
| Nbr of stocks (in thousands) | 401,744 | 401,744 | 401,744 | 401,744 | 401,744 | 401,744 |
| Reference price 2 | 8.800 | 7.650 | 7.630 | 10.86 | 13.61 | 11.06 |
| Announcement Date | 26/04/19 | 28/04/20 | 26/04/21 | 25/04/22 | 24/04/23 | 25/04/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 970.7 | 1,006 | 777.3 | 1,054 | 1,243 | 1,209 |
| EBITDA 1 | 259.1 | 245.1 | 77.99 | 201.9 | 371.1 | 341.6 |
| EBIT 1 | 178.8 | 163.8 | -7.632 | 115.5 | 280.8 | 247.9 |
| Operating Margin | 18.42% | 16.29% | -0.98% | 10.96% | 22.6% | 20.5% |
| Earnings before Tax (EBT) 1 | 188.8 | 160.1 | -665.1 | 93.54 | 290.5 | 177 |
| Net income 1 | 149.2 | 120.3 | -687.7 | 66.48 | 218.8 | 126.2 |
| Net margin | 15.37% | 11.97% | -88.47% | 6.31% | 17.61% | 10.44% |
| EPS 2 | 0.3700 | 0.3000 | -1.710 | 0.1700 | 0.5400 | 0.3100 |
| Free Cash Flow 1 | 139.4 | 122.8 | 104.9 | 27.39 | 263.7 | -19.48 |
| FCF margin | 14.36% | 12.21% | 13.5% | 2.6% | 21.22% | -1.61% |
| FCF Conversion (EBITDA) | 53.79% | 50.09% | 134.57% | 13.57% | 71.06% | - |
| FCF Conversion (Net income) | 93.44% | 102.02% | - | 41.2% | 120.54% | - |
| Dividend per Share 2 | 0.0800 | 0.0700 | - | - | - | - |
| Announcement Date | 26/04/19 | 28/04/20 | 26/04/21 | 25/04/22 | 24/04/23 | 25/04/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 369 | 407 | 474 | 288 | 494 | 473 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | 139 | 123 | 105 | 27.4 | 264 | -19.5 |
| ROE (net income / shareholders' equity) | 5.86% | 4.61% | -28.3% | 3.13% | 9.54% | 5.11% |
| ROA (Net income/ Total Assets) | 3.54% | 3.19% | -0.17% | 2.74% | 6.02% | 5.03% |
| Assets 1 | 4,216 | 3,773 | 412,761 | 2,424 | 3,633 | 2,509 |
| Book Value Per Share 2 | 6.580 | 6.800 | 5.020 | 5.190 | 5.660 | 5.470 |
| Cash Flow per Share 2 | 0.8500 | 0.8400 | 1.020 | 0.5900 | 1.100 | 1.240 |
| Capex 1 | 26.8 | 27.2 | 35.1 | 85.4 | 54.1 | 66.1 |
| Capex / Sales | 2.76% | 2.71% | 4.51% | 8.1% | 4.36% | 5.47% |
| Announcement Date | 26/04/19 | 28/04/20 | 26/04/21 | 25/04/22 | 24/04/23 | 25/04/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -18.26% | 502M | |
| +22.69% | 43.81B | |
| +25.56% | 23.01B | |
| +17.92% | 15.27B | |
| +8.91% | 13.68B | |
| +42.72% | 11.96B | |
| -7.49% | 6.98B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +13.26% | 5.59B |
- Stock Market
- Equities
- 300434 Stock
- Financials Sichuan Goldstone Asia Pharmaceutical Inc.
